Pituitary neuroendocrine tumors (PitNETs) are divided into multiple histological subtypes,
which determine their clinical and biological variable behavior. Despite their benign …

Therapeutic shrinkage of prolactinomas with dopamine agonists achieves clinical benefit but
can expose fistulae that have arisen as a result of bony erosion of the sella floor and anterior …

Background Giant prolactinoma (> 4 cm in dimension) is a rare disorder. Invasive
macroprolactinoma has the potential to cause base of skull erosion and extend into the …

Dopamine agonists are the first-line treatment of prolactinomas. The risk of developing de
novo psychiatric symptoms during dopamine agonist therapy is low. Herein, we report the …

Purpose Giant prolactinomas, which have extremely large sizes and high prolactin (PRL)
values, are rarely seen. Although medical therapy is effective, surgical treatment is more …

Introduction. Giant prolactinoma (GP) is a rare pituitary lactotropic cell tumor larger than 4 cm
in its widest dimension, and is less likely than a smaller prolactinoma to achieve prolactin …

The most common type of functioning pituitary adenomas is prolactinomas; unlike other
types, they are treated medically with dopamine agonists (DA). This treatment aims to …

Objective Determining the etiology of hyperprolactinemia is fundamental for selecting the
most appropriate treatment strategy. The aim of this study was to evaluate the usefulness …

Background: Prolactinomas are the most common type of functional pituitary tumours. The
objective of this study was to determine demographic profile of patients with prolactinomas …

Background The management of giant prolactinomas remains a major challenge, despite
dopamine agonists being the first line of treatment, owing to its efficacy to normalize …